Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
Open Access
- 13 January 2022
- journal article
- research article
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (3) , 1-14
Abstract
The interleukin 6 (IL‑6)/glycoprotein 130 (GP130)/signal transducer and activator of transcription 3 (STAT3) signalling pathway, with GP130 as an intermediate membrane receptor, is involved in the survival, metastasis, and resistance of ovarian cancer. Bazedoxifene, an FDA‑approved drug, is an inhibitor of GP130 and a selective estrogen modulator (SERM). We studied the mechanism of the combination therapy of bazedoxifene and paclitaxel in inhibiting the IL‑6‑mediated GP130/STAT3 signaling pathway in ovarian cancer. Surface plasmon resonance (SPR) was used to assess the binding of bazedoxifene to GP130. Migration, invasion, and apoptosis of ovarian cancer cells were assessed using bazedoxifene and paclitaxel. In addition, we determined the effects of bazedoxifene and paclitaxel alone or in combination on the GP130/STAT3 pathway and epithelial‑mesenchymal transition (EMT). The results revealed that the combination of bazedoxifene and paclitaxel suppressed cell viability, migration, and invasion in the ovarian cancer cells. In addition, the combination treatment increased apoptosis. Furthermore, bazedoxifene combined with paclitaxel inhibited the growth of ovarian cancer cells in a xenograft tumour model. This combination reduced STAT3 phosphorylation and suppressed gene expression and EMT. In conclusion, inhibition of GP130/STAT3 signalling and EMT via a combination of bazedoxifene and paclitaxel could be used as a therapeutic strategy by which to overcome ovarian cancer.Keywords
This publication has 40 references indexed in Scilit:
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumoursNature, 2008
- CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cellsCancer Chemotherapy and Pharmacology, 2008
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptorNature Structural & Molecular Biology, 2005
- Mechanisms of Taxol resistance related to microtubulesOncogene, 2003
- STATs: transcriptional control and biological impactNature Reviews Molecular Cell Biology, 2002
- Constitutive Activation of Stat 3 Oncogene Product in Human Ovarian Carcinoma CellsGynecologic Oncology, 2000
- Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene, 2000
- Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cellsLeukemia, 1999